[1] PAN B T,JOHNSTONE R M.Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro:selective externalization of the receptor[J].Cell,1983,33(3):967-978.
[2] JOHNSTONE R M,ADAM M,HAMMOND J R,et al.Vesicle formation during reticulocyte maturation.Association of plasma membrane activities with released vesicles (exosomes)[J].J Biol Chem,1987,262(19):9412-9420.
[3] THÉRY C.Exosomes:secreted vesicles and intercellular communications[J].F1000 Biol Rep,2011,3:15.
[4] TANG M K,WONG A S.Exosomes:emerging biomarkers and targets for ovarian cancer[J].Cancer Lett,2015,367(1):26-33.
[5] BRETZ N P,RIDINGER J,RUPP A K,et al.Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling[J].J Biol Chem,2013,288(51):36691-36702.
[6] BATTKE C,RUISS R,WELSCH U,et al.Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC[J].Cancer Immunol Immunother,2011,60(5):639-648.
[7] PENG P,YAN Y,KENG S.Exosomes in the ascites of ovarian cancer patients:origin and effects on anti-tumor immunity[J].Oncol Rep,2011,25(3):749-762.
[8] LIANG B,PENG P,CHEN S,et al.Characterization and proteomic analysis of ovarian cancer-derived exosomes[J].J Proteomics,2013,80:171-182.
[9] KELLER S,KÖNIG A K,MARMÉ F,et al.Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes[J].Cancer Lett,2009,278(1):73-81.
[10] RUNZ S,KELLER S,RUPP C,et al.Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM[J].Gynecol Oncol,2007,107(3):563-571.
[11] STOECK A,KELLER S,RIEDLE S,et al.A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44[J].Biochem J,2006,393(Pt 3):609-618.
[12] ESCREVENTE C,GRAMMEL N,KANDZIA S,et al.Sialoglycoproteins and N-glycans from secreted exosomes of ovarian carcinoma cells[J].PLoS One,2013,8(10):e78631.
[13] SZAJNIK M,CZYSTOWSKA M,SZCZEPANSKI M J,et al.Tumor-derived microvesicles induce,expand and up-regulate biological activities of human regulatory T cells (Treg)[J].PLoS One,2010,5(7):e11469.
[14] ANDRE F,SCHARTZ N E,MOVASSAGH M,et al.Malignant effusions and immunogenic tumour-derived exosomes[J].Lancet,2002,360(9329):295-305.
[15] BARD M P,HEGMANS J P,HEMMES A,et al.Proteomic analysis of exosomes isolated from human malignant pleural effusions[J].Am J Respir Cell Mol Biol,2004,31(1):114-121.
[16] TAYLOR D D,GERCEL-TAYLOR C.MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer[J].Gynecol Oncol,2008,110(1):13-21.
[17] KOBAYASHI M,SALOMON C,TAPIA J,et al.Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200[J].J Transl Med,2014,12:4.
[18] GE R,TAN E,SHARGHI-NAMINI S,et al.Exosomes in cancer microenvironment and beyond:have we overlooked these extracellular messengers?[J].Cancer Microenviron,2012,5(3):323-332.
[19] BEACH A,ZHANG H G,RATAJCZAK M Z,et al.Exosomes:an overview of biogenesis,composition and role in ovarian cancer[J].J Ovarian Res,2014,7:14.
[20] GUTWEIN P,STOECK A,RIEDLE S,et al.Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells[J].Clin Cancer Res,2005,(7):2492-2501.
[21] SAFAEI R,LARSON B J,CHENG T C,et al.Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drugresistant human ovarian carcinoma cells[J].Mol Cancer Ther,2005,4(10):1595-1604.
[22] ZHANG B,CAI F F,ZHONG X Y.An overview of biomarkers for the ovarian cancer diagnosis[J].Eur J Obstet Gynecol Reprod Biol,2011,158(2):119-123.
[23] SZAJNIK M,DERBIS M,LACH M,et al.Exosomes in plasma of patients with ovarian carcinoma:potential biomarkers of tumor progression and response to therapy[J].Gynecol Obstet (Sunnyvale),2013,29(Suppl 4):3.
[24] LI J,SHERMAN-BAUST C A,TSAI-TURTON M,et al.Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer[J].BMC Cancer,2009,9:244.
[25] IM H,SHAO H,PARK Y I,et al.Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor[J].Nat Biotechnol,2014,32(5):490-495.
[26] PINK R C,SAMUEL P,MASSA D,et al.The passenger strand,miR-21-3p,plays a role in mediating cisplatin resistance in ovarian cancer cells[J].Gynecol Oncol,2015,137(1):143-151.
[27] LU J,GETZ G,MISKA E A,et al.MicroRNA expression pro-files classify human cancers[J].Nature,2005,435(7043):834-838.
[28] MELO S A,SUGIMOTO H,O'Connell J T,et al.Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis[J].Cancer Cell,2014,26(5):707-721.
[29] MARLEAU A M,CHEN C S,JOYCE J A,et al.Exosome removal as a therapeutic adjuvant in cancer[J].J Transl Med,2012,10:134.
[30] HURLEY J H,ODORIZZI G.Get on the exosome bus with ALIX[J].Nat Cell Biol,2012,14(7):654-655.
[31] KANDALAFT L E,MOTZ G T,DURAISWAMY J,et al.Tumor immune surveillance and ovarian cancer:lessons on immune mediated tumor rejection or tolerance[J].Cancer Metastasis Rev,2011,30(1):141-151.
[32] RAPOSO G,NIJMAN H W,STOORVOGEL W,et al.B lymphocytes secrete antigen-presenting vesicles[J].J Exp Med,1996,183(3):1161-1172.
[33] ESCUDIER B,DORVAL T,CHAPUT N,et al.Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derivedexosomes:results of the first phase Ⅰ clinical trial[J].J Transl Med,2005,3(1):10.
[34] ZHANG L,CONEJO-GARCIA J R,KATSAROS D,et al.Intratumoral T cells,recurrence,and survival in epithelial ovarian cancer[J].N Engl J Med,2003,348(3):203-213.
[35] NAVABI H,CROSTON D,HOBOT J,et al.Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial[J].Blood Cells Mol Dis,2005,35(2):149-152.
[36] SUN D,ZHUANG X,XIANG X,et al.A novel nanoparticle drug delivery system:the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes[J].Mol Ther,2010,18(9):1606-1614.
[37] MUNAGALA R,AQIL F,JEYABALAN J,et al.Bovine milk-derived exosomes for drug delivery[J].Cancer Lett,2016,371(1):48-61.
[38] SAARI H,LÁZARO-IBÁÑEZ E,VIITALA T,et al.Microvesicle-and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells[J].J Control Release,2015,220:727-737.
[39] CAI Y Y,LIN W P,LI A P,et al.Combined effects of curcumin and triptolide on an ovarian cancer cell line[J].Asian Pac J Cancer Prev,2013,14(7):4267-4271. |
